What are the risks associated with taking Mineralocorticoid receptor antagonist?
The risks associated with taking Mineralocorticoid receptor antagonist include gynaecomastia, renal failure, and other breast disorders. The quality of the evidence for these risks is rated as moderate to very low due to risk of bias, imprecision, and heterogeneity. The relative effect of Mineralocorticoid receptor antagonist compared to placebo is reported to be from 12 fewer to 13 more, from 31 more to 177 more, and from 6 fewer to 29 more respectively. The Peto odds ratio is reported to be from 3 fewer to 3 more. These risks may be further downgraded by one or two increments depending on the confidence interval and the majority of the evidence being at high or very high risk of bias.